- Email: [email protected]
Addenda
. . CHEST -
-
Supplement ANTITHROMBOTIC ANDTHROMBOLYTIC THERAPY 8THED: ACCP GUIDELINES
Addenda In th e a rticle by Match ar and Mark, "St rategies for In co rporating Resource Allocati on and Ecou omic C o ns ide ra tio ns: Ame rican Co llege o f C he st Ph ysicians Evid en ee-l3 ased C linica l P ractice Cu idelin es (Sth Edition )" (C hest 2008; 133[supplj :132S-140S ), th e con flict of inte res t di scl osu res from th e au tho rs were in adv ertently left ou t. Dr. Mark d isclos es th at he ha s receiv ed gra nt mo nies from th e National H ea rt , Lung, and Blood In stitute , th e National Institutes of Health , th e Agency for Heulthcnrc Heseu rch ami Quality, Proctor & Gamble, Pfize r. Medtronic , Abdon Inc ., Medicure, Innocoll , and St. [ud cs, He IHL~ also received co nsulta n t fees from Aventis, Ast raZ en cea , Medtronic, and Novartis, Dr. Matchar reveals no real or potential conflict s of int er est or commitment. In th e article hy Kcnron et ul, "Au ti th ro m bo tlc Therapy for Venous Thromboemoholic Disease ; American College o f Ch est Ph ys lc inns Evklence -Bnsed Clinical Practice Guidelines (St h Ed it ion )" (C hest 2008 ; 133 [supplj :454S-545S ), th e co n-
www.chestjournal.org
Flict of interest di sclosures from the authors were inadvertently left oul. They nrc as follow s: Dr. Kearon discloses that he ha s received grant monies fro m th e Canadi an Institutes for Health Hesearch and th e He art and Stroke Foundation nf C:IlI:1t!a. He is also on an adv iso ry co m m Utec for GlaxoSmUhKline nnd Boehringer lngelhcun. Dr. Agnelll reveals IIlI rea l or pot entinl co nfli c ts of int erest or co mmltmeut. Dr. Coldhnber discloses th at he hns receiv ed grant moni es [rom Mitsnh ishi , Boeh rlnger ln gelhebn, Snno fl-Ave n tls , Ei sai, GlaxoSmithKline, and AslraZl:neca . He has also rec eived co ns ultan t fe es from Suuofi-Aveutis. El sui , Bristol-M ye rs Squihh, and Boehringcr Iugelheim, Dr. Raskob discloses that he has se rve d on the Speaker's Bureau and ad visory committees and has received consultant fees from Buyer, 8MS. Duiichi-Sankyo, Pfiz er, Sunofl-Aventis, Tuk edo. a III I Boehriuge r Ingelh eim. Dr. Comerotta discloses th ai Ill' is Oil Speaker's Bureaus for Suno fl-Aveutts. Bristol-Myers SIIUibb . an d GIII)(oSllIithK lin e . and serves on 1111 advisorv co m mittee for ConvaTec and Bacchus Vascular. li e is 'nlso a shareholde r of LeMuitre Vascular .
CHEST /133/6/ JUNE, 2006 SUPPLEMENT
9695
-
Supplement ANTITHROMBOTIC ANDTHROMBOLYTIC THERAPY 8THED: ACCP GUIDELINES
Addenda In th e a rticle by Match ar and Mark, "St rategies for In co rporating Resource Allocati on and Ecou omic C o ns ide ra tio ns: Ame rican Co llege o f C he st Ph ysicians Evid en ee-l3 ased C linica l P ractice Cu idelin es (Sth Edition )" (C hest 2008; 133[supplj :132S-140S ), th e con flict of inte res t di scl osu res from th e au tho rs were in adv ertently left ou t. Dr. Mark d isclos es th at he ha s receiv ed gra nt mo nies from th e National H ea rt , Lung, and Blood In stitute , th e National Institutes of Health , th e Agency for Heulthcnrc Heseu rch ami Quality, Proctor & Gamble, Pfize r. Medtronic , Abdon Inc ., Medicure, Innocoll , and St. [ud cs, He IHL~ also received co nsulta n t fees from Aventis, Ast raZ en cea , Medtronic, and Novartis, Dr. Matchar reveals no real or potential conflict s of int er est or commitment. In th e article hy Kcnron et ul, "Au ti th ro m bo tlc Therapy for Venous Thromboemoholic Disease ; American College o f Ch est Ph ys lc inns Evklence -Bnsed Clinical Practice Guidelines (St h Ed it ion )" (C hest 2008 ; 133 [supplj :454S-545S ), th e co n-
www.chestjournal.org
Flict of interest di sclosures from the authors were inadvertently left oul. They nrc as follow s: Dr. Kearon discloses that he ha s received grant monies fro m th e Canadi an Institutes for Health Hesearch and th e He art and Stroke Foundation nf C:IlI:1t!a. He is also on an adv iso ry co m m Utec for GlaxoSmUhKline nnd Boehringer lngelhcun. Dr. Agnelll reveals IIlI rea l or pot entinl co nfli c ts of int erest or co mmltmeut. Dr. Coldhnber discloses th at he hns receiv ed grant moni es [rom Mitsnh ishi , Boeh rlnger ln gelhebn, Snno fl-Ave n tls , Ei sai, GlaxoSmithKline, and AslraZl:neca . He has also rec eived co ns ultan t fe es from Suuofi-Aveutis. El sui , Bristol-M ye rs Squihh, and Boehringcr Iugelheim, Dr. Raskob discloses that he has se rve d on the Speaker's Bureau and ad visory committees and has received consultant fees from Buyer, 8MS. Duiichi-Sankyo, Pfiz er, Sunofl-Aventis, Tuk edo. a III I Boehriuge r Ingelh eim. Dr. Comerotta discloses th ai Ill' is Oil Speaker's Bureaus for Suno fl-Aveutts. Bristol-Myers SIIUibb . an d GIII)(oSllIithK lin e . and serves on 1111 advisorv co m mittee for ConvaTec and Bacchus Vascular. li e is 'nlso a shareholde r of LeMuitre Vascular .
CHEST /133/6/ JUNE, 2006 SUPPLEMENT
9695